Single Base Editing HBA2 Gene Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating α-thalassemia, such as gene overexpression and nuclease cleavage, pose safety concerns like insertional mutagenesis, off-target risks, and low efficiency, which are insufficient to achieve therapeutic levels.
Innovation Solution
A method for repairing an HBA2 gene mutation using single base editing, which involves contacting a single base editor and a guide RNA (gRNA) with the HBA2 gene sequence to precisely edit the target cytosine base, converting it from CAA to TAA without causing double-strand breaks or affecting genome stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional nuclease cleavage methods are used to repair HBA2 gene mutations, then gene repair can be achieved, but double-strand breaks are introduced causing off-target risks and genomic instability
Solution Approach 1:
The invention changes the fundamental parameter of the editing mechanism from nuclease-based double-strand break to base deamination single-base conversion. By using base editors that directly convert C to T at the mutation site without inducing double-strand breaks, the method eliminates off-target risks and genomic instability while maintaining reliable gene repair
Solution Approach 2:
The invention extracts and removes the harmful nuclease cleavage function from the gene editing process. By using modified base editors that lack nuclease activity but retain deamination capability, the method eliminates the harmful double-strand break effect while preserving the beneficial gene repair function
2Quantity of substance
If gene overexpression therapy is used to treat α-thalassemia, then globin expression can be increased, but random integration occurs causing insertional mutagenesis and potential malignancies
Solution Approach 1:
The invention converts the harmful random integration mechanism into a beneficial precise base substitution mechanism. Instead of randomly integrating globin gene copies that may disrupt oncogenes or tumor suppressors, the method precisely converts the single base mutation (CAA to TAA) back to wild type, achieving therapeutic globin expression without insertional mutagenesis
Solution Approach 2:
The invention changes the therapeutic mechanism from quantitative gene overexpression to qualitative base sequence correction. By fixing the underlying genetic defect rather than simply increasing gene dosage, the method achieves sustained therapeutic expression without the safety risks of random integration
3Reliability
If homology-directed gene repair after cleavage is used, then HBA2 gene can be repaired, but the efficiency is low and insufficient to achieve therapeutic levels
Solution Approach 1:
The invention changes the repair mechanism from homology-directed repair (HDR) requiring donor templates to direct base deamination. By using modified base editors that directly convert C to T at the mutation site through deamination, the method achieves high editing efficiency without requiring homology-directed repair pathways, thereby overcoming the efficiency limitation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for precise and efficient repair of the Hb-CS mutation with high safety, balancing the expression of α/β globin, and reducing the risk of oncogene activation or tumor suppressor gene inactivation.
Implementation Method 1
deaminating the target cytosine base of mutated codon (CAA) at CD142 of HBA2 gene, to convert cytosine to thymine (TAA)
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
A method for repairing HBA2 gene mutations by single base editing and use thereof, belonging to the technical field of gene editing. The method comprises the following steps: contacting a single base editor and gRNA with an HBA gene sequence to be edited and repaired, deaminating the codon target cytosine base at CD142 in the HBA gene sequence, and converting the cytosine into thymine. According to the method, pathogenic mutation sites can be accurately edited without generating double-strand breaks and affecting chromatin conformation and genome stability, without generating random insertions of large-fragment genes into genomes, which have a low influence on cancer gene activation or tumor-inhibiting gene inactivation, and without generating random insertions/deletions at other sites of a genome. The expression of the repaired target gene is regulated by all regulatory elements of natural HBA2; therefore, the method is very safe and can also better balance the expression of α/β globin.